Based on results from a phase 3 trial, a bevacizumab biosimilar, bevacizumab-adcd, was approved by the FDA for patients with metastatic or recurrent non-squamous non–small cell lung in addition to 5 ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved bevacizumab-adcd for treatment of six cancer types, according to a press release from the ...